May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?


Journal

Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 30 03 2020
accepted: 21 04 2020
pubmed: 29 4 2020
medline: 12 9 2020
entrez: 29 4 2020
Statut: ppublish

Résumé

COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.

Identifiants

pubmed: 32344304
pii: 109751
pii: S0306-9877(20)30590-9
doi: 10.1016/j.mehy.2020.109751
pmc: PMC7175887
doi:

Substances chimiques

5-alpha Reductase Inhibitors 0
Finasteride 57GNO57U7G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109751

Informations de copyright

© 2020 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Am J Respir Crit Care Med. 2004 Aug 1;170(3):296-305
pubmed: 15117747
J Biol Chem. 2007 Feb 9;282(6):3968-76
pubmed: 17158884
J Cell Sci. 1993 Jun;105 ( Pt 2):423-32
pubmed: 8408275
J Clin Endocrinol Metab. 2002 Aug;87(8):3883-92
pubmed: 12161528
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Adv Urol. 2012;2012:530121
pubmed: 22235201
Reprod Biol Endocrinol. 2010 Jan 08;8:2
pubmed: 20064212
Proc Am Thorac Soc. 2009 Dec 1;6(7):588-95
pubmed: 19934354
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Urology. 2003 Apr;61(4 Suppl 1):2-7
pubmed: 12657354
Asian J Urol. 2018 Jan;5(1):28-32
pubmed: 29379733
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856

Auteurs

Jan Adamowicz (J)

Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Curie-Skłodowskiej 9, 85 094 Bydgoszcz, Poland.
Reconstructive Urology Working Group, Young Academic Urologists, European Association of Urology, Poland.

Kajetan Juszczak (K)

Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Curie-Skłodowskiej 9, 85 094 Bydgoszcz, Poland.

Tomasz Drewa (T)

Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Curie-Skłodowskiej 9, 85 094 Bydgoszcz, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH